CMS Reopens Coverage Determination on Next Generation Sequencing for Cancer Patients
May 2, 2019
CMS Monday (4/29/2019) reopened its national coverage determination (NCD) for next-generation sequencing (NGS).
The move follows pressure from healthcare organizations that argued the agency's original decision on NGS would prevent Medicare beneficiaries with early-stage cancer from accessing the tests.
CMS, in a tracking sheet, said it is reconsidering only the evidence available for tests of germline mutations to identify patients with hereditary cancer who may benefit from targeted treatments based on their test results.